Replies to post #29714 on Biotech Values

[DewDiligence]

> ANDS / NVS: I don't see a distinct reason for any fallout.<

Investors are questioning the extent of NVS’ commitment to ANA975. (If 975 is such a great immunomodulator, why does NVS need another?)

I wouldn’t make too much of this, but I think it’s silly to deny that there’s a simple reason why ANDS is down sharply today.